Technology-based Company.

Engaged in advancing innovative solutions for large-scale market applications

Company Overview

Protecting Against Biological Threats

Polyrizon is a clinical development biotech company specializing in the development of innovative nasal gels to provide preventative treatment against a wide range of biological assaults, such as viruses, including COVID-19 and influenza, as well as allergens and other airborne pathogens.

Polyrizon’s proprietary Capture and ContainTM (C&C) hydrogel platform, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and forms a thin protective shield containment barrier in the nasal cavity to prevent infection.

Polyrizon is further developing certain aspects of its C&C hydrogel platform such as the bioadhesion and prolonged retention at the nasal deposition site for improved intranasal delivery of drugs. We refer to our platform technology that is focused on nasal delivery of APIs as Trap &TargetTM (T&T).


Facts and Figures


Medigus’ holdings


Months to first
efficiency trial results


Option to increase
holdings to